Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norovirus GI.1/GII.4 Bivalent VLP Vaccine Dose Finding Study
NCT02038907Phase 2Completed
- Sponsor
- Takeda
- Start
- Mar 2014
- Primary completion
- Jun 2015
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of NoV GI.1/GII.4 bivalent VLP vaccine in norovirus infection, sponsored by Takeda. Started Mar 2014; status: completed.
02
Drugs
NoV GI.1/GII.4 bivalent VLP vaccine
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT02038907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02038907.